Tailor-made drugs to treat epilepsy or cardiovascular diseases

Tailor-made drugs to treat epilepsy or cardiovascular diseases
Molecular interactions of the receptor blocker JNJ-31020028 (light green; nitrogen atoms highlighted in blue, oxygen atoms in red) at the human Y2 receptor (grey). With seven helices, the receptor sits in the cell membrane and is accessible to its ligands from the outer side. Credit: Dr Anette Kaiser

In order for a drug to be effective at the right places in the body, it helps if scientists can predict as accurately as possible how the molecules of that drug will interact with human cells. In a joint research project, scientists from Collaborative Research Centre 1423 at Leipzig University and the Chinese Academy of Sciences in Shanghai have succeeded in elucidating such a structure, namely that of the neuropeptide Y receptor Y2 with one of its ligands. This is the first time that a molecular blueprint for this receptor is available, which will enable the development of tailor-made new drugs, for example to treat epilepsy or cardiovascular diseases. The researchers' findings have now been published in Nature Communications.

The Y2 receptor plays an important role, especially in the peripheral nervous system and in the brain, as it is considered one of the 'satiety .' It also plays a role in epilepsy as well as in cardiovascular diseases. If these diseases are to be treated with drugs that block the Y2 receptor, it is important to ensure that the can target this receptor precisely and exclusively, because some closely related receptors would have exactly the opposite effect. When developing novel drugs, it is therefore essential to obtain highly targeted compounds and to have precise knowledge of their molecular properties.

Researchers led by Professor Annette Beck-Sickinger and Dr. Anette Kaiser at Leipzig University have succeeded in showing on the molecular level how substances can block the Y2 receptor. Working with their colleagues in Shanghai, they were able to explain the with a bound ligand, validate it by means of numerous biochemical investigations, and transfer it to other systems. The new study also reveals that Y2 receptor blockers bind differently than comparable molecules at the closely related Y1 subtype. This will facilitate further knowledge-based development of selective compounds at both receptors.

The investigation of this receptor family with its endogenous ligands as well as other clinically relevant compounds is one focus of Collaborative Research Centre 1423. The CRC 1423 is a research project being funded for four years by the German Research Foundation (DFG), in which four funding institutions are involved: Leipzig University, Martin Luther University Halle-Wittenberg, Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine. Researchers from these institutions with backgrounds in biochemistry, biomedicine and are collaborating on an interdisciplinary basis to gain a comprehensive understanding of the effects of structural dynamics on the function of G protein-coupled receptors. The Collaborative Research Centre comprises a total of 19 sub-projects.


Explore further

Inactivated human muscarinic receptors help researchers find paths to effective drugs

More information: Tingting Tang et al, Structural basis for ligand recognition of the neuropeptide Y Y2 receptor, Nature Communications (2021). DOI: 10.1038/s41467-021-21030-9
Journal information: Nature Communications

Provided by Universität Leipzig
Citation: Tailor-made drugs to treat epilepsy or cardiovascular diseases (2021, February 10) retrieved 18 April 2021 from https://medicalxpress.com/news/2021-02-tailor-made-drugs-epilepsy-cardiovascular-diseases.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments